Anna Olsson-Brown
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Anna Olsson-Brown has a total of 108 co-authors. Here are the top co-authors by number of shared publications:
- Daniel F. Carr
University of Liverpool
3 shared publications - Mark Ross Middleton
Department of Oncology, University of Oxford, Oxford, UK
3 shared publications - Munir Pirmohamed
University of Liverpool Department of Pharmacology and Therapeutics
3 shared publications - Anne Mary Dickinson
Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK
2 shared publications - Benjamin Peter Fairfax
Department of Oncology, University of Oxford, Oxford, UK
2 shared publications - Carol Jolly
Department Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology University of Liverpool Liverpool UK
2 shared publications
Latest Publications
- Open Access
- 6 October 2026
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 22 (1)
Immune checkpoint inhibition enhances memory T-cell responses to CEF(T), SARS-CoV-2 spike proteins and ChAdOx1 nCoV-19
- 6 October 2026
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 22 (1)
Open AccessImmune checkpoint inhibition enhances memory T-cell responses to CEF(T), SARS-CoV-2 spike proteins and ChAdOx1 nCoV-19
- Open Access
- 6 March 2026
- Published by Elsevier in SSRN Electronic Journal
Impact of concurrent CMV colitis on clinical outcomes in immune checkpoint inhibitor‒induced colitis
Background and aims Immune checkpoint inhibitors (ICI) frequently trigger ICI-colitis, commonly leading to ICI discontinuation. With increasing ICI use, ICI-colitis is an emerging clinical challenge. Cytomegalovirus (CMV) infection is known to occur in ICI-colitis, but its prevalence, risk factors, and impact are poorly defined. This study aimed to characterise colonic CMV infection in ICI-colitis using robust definitions and a CMV-negative comparator group. MethodsWe retrospectively analysed consecutive ICI- treated patients with endoscopically and/or histologically confirmed ICI-colitis at two UK hospitals between 2015 and 2024. Clinical, endoscopic (Mayo Endoscopic Score, MES), treatment and oncologic outcome data were collected. CMV was identified by immunohistochemistry (IHC) on colonic biopsies. CMV-positive cases were compared with CMV-negative controls using chi- squared, Mann-Whitney U and multivariable regression analyses. ResultsAmong 249 ICI-colitis patients, CMV- colitis was detected in 21 (8.4%). CMV-positive patients were more likely to receive dual ICI therapy, have bloody stool (OR 2.7, p=0.038) and have higher endoscopic severity (MES 2–3; OR 4.1, p<0.01), despite similar diarrhoea grades. Prior infliximab exposure was strongly associated with CMV colitis (OR 5.2, p=0.002). CMV-positive cases more frequently required escalation to advanced therapy (80% vs 41.5%; OR 5.6, p=0.002), remaining significant after adjustment for endoscopic severity (p=0.049). Colectomy rates were higher albeit low overall. Antiviral therapy did not significantly affect corticosteroid duration or recurrence, and CMV status did not influence overall or progression-free survival. ConclusionConcurrent CMV colitis occurs in a notable subset of ICI-colitis patients and may worsen disease severity, highlighting the importance of endoscopic biopsy, especially in steroid-refractory cases.
- 6 March 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessImpact of concurrent CMV colitis on clinical outcomes in immune checkpoint inhibitor‒induced colitis
Background and aims Immune checkpoint inhibitors (ICI) frequently trigger ICI-colitis, commonly leading to ICI discontinuation. With increasing ICI use, ICI-colitis is an emerging clinical challenge. Cytomegalovirus (CMV) infection is known to occur in ICI-colitis, but its prevalence, risk factors, and impact are poorly defined. This study aimed to characterise colonic CMV infection in ICI-colitis using robust definitions and a CMV-negative comparator group. MethodsWe retrospectively analysed consecutive ICI- treated patients with endoscopically and/or histologically confirmed ICI-colitis at two UK hospitals between 2015 and 2024. Clinical, endoscopic (Mayo Endoscopic Score, MES), treatment and oncologic outcome data were collected. CMV was identified by immunohistochemistry (IHC) on colonic biopsies. CMV-positive cases were compared with CMV-negative controls using chi- squared, Mann-Whitney U and multivariable regression analyses. ResultsAmong 249 ICI-colitis patients, CMV- colitis was detected in 21 (8.4%). CMV-positive patients were more likely to receive dual ICI therapy, have bloody stool (OR 2.7, p=0.038) and have higher endoscopic severity (MES 2–3; OR 4.1, p<0.01), despite similar diarrhoea grades. Prior infliximab exposure was strongly associated with CMV colitis (OR 5.2, p=0.002). CMV-positive cases more frequently required escalation to advanced therapy (80% vs 41.5%; OR 5.6, p=0.002), remaining significant after adjustment for endoscopic severity (p=0.049). Colectomy rates were higher albeit low overall. Antiviral therapy did not significantly affect corticosteroid duration or recurrence, and CMV status did not influence overall or progression-free survival. ConclusionConcurrent CMV colitis occurs in a notable subset of ICI-colitis patients and may worsen disease severity, highlighting the importance of endoscopic biopsy, especially in steroid-refractory cases.
- Open Access
- 2 June 2023
- Published by Wiley in The Journal of Dermatology
- Vol. 50 (9) , 1129-1139
TNF‐α induced extracellular release of keratinocyte high‐mobility group box 1 in Stevens‐Johnson syndrome/toxic epidermal necrolysis: Biomarker and putative mechanism of pathogenesis
Decreased epidermal high‐mobility group box 1 (HMGB1) expression is an early marker of epidermal injury in Stevens–Johnson syndrome/toxic epidermal necrolysis (SJS/TEN). Etanercept, an anti‐tumor necrosis factor therapeutic, is effective in the treatment of SJS/TEN. The objective was to characterize antitumor necrosis factor‐alpha (TNF‐α)‐mediated HMGB1 keratinocyte/epidermal release and etanercept modulation. HMGB1 release from TNF‐α treated (± etanercept), or doxycycline‐inducible RIPK3 or Bak‐expressing human keratinocyte cells (HaCaTs) was determined by western blot/ELISA. Healthy skin explants were treated with TNF‐α or serum (1:10 dilution) from immune checkpoint inhibitor‐tolerant, lichenoid dermatitis or SJS/TEN patients ± etanercept. Histological and immunohistochemical analysis of HMGB1 was undertaken. TNF‐α induced HMGB1 release in vitro via both necroptosis and apoptosis. Exposure of skin explants to TNF‐α or SJS/TEN serum resulted in significant epidermal toxicity/detachment with substantial HMGB1 release which was attenuated by etanercept. Whole‐slide image analysis of biopsies demonstrated significantly lower epidermal HMGB1 in pre‐blistered SJS/TEN versus control (P < 0.05). Keratinocyte HMGB1 release, predominantly caused by necroptosis, can be attenuated by etanercept. Although TNF‐α is a key mediator of epidermal HMGB1 release, other cytokines/cytotoxic proteins also contribute. Skin explant models represent a potential model of SJS/TEN that could be utilized for further mechanistic studies and targeted therapy screening.
- 2 June 2023
- Published by Wiley in The Journal of Dermatology
- Vol. 50 (9) , 1129-1139
Open AccessTNF‐α induced extracellular release of keratinocyte high‐mobility group box 1 in Stevens‐Johnson syndrome/toxic epidermal necrolysis: Biomarker and putative mechanism of pathogenesis
Decreased epidermal high‐mobility group box 1 (HMGB1) expression is an early marker of epidermal injury in Stevens–Johnson syndrome/toxic epidermal necrolysis (SJS/TEN). Etanercept, an anti‐tumor necrosis factor therapeutic, is effective in the treatment of SJS/TEN. The objective was to characterize antitumor necrosis factor‐alpha (TNF‐α)‐mediated HMGB1 keratinocyte/epidermal release and etanercept modulation. HMGB1 release from TNF‐α treated (± etanercept), or doxycycline‐inducible RIPK3 or Bak‐expressing human keratinocyte cells (HaCaTs) was determined by western blot/ELISA. Healthy skin explants were treated with TNF‐α or serum (1:10 dilution) from immune checkpoint inhibitor‐tolerant, lichenoid dermatitis or SJS/TEN patients ± etanercept. Histological and immunohistochemical analysis of HMGB1 was undertaken. TNF‐α induced HMGB1 release in vitro via both necroptosis and apoptosis. Exposure of skin explants to TNF‐α or SJS/TEN serum resulted in significant epidermal toxicity/detachment with substantial HMGB1 release which was attenuated by etanercept. Whole‐slide image analysis of biopsies demonstrated significantly lower epidermal HMGB1 in pre‐blistered SJS/TEN versus control (P < 0.05). Keratinocyte HMGB1 release, predominantly caused by necroptosis, can be attenuated by etanercept. Although TNF‐α is a key mediator of epidermal HMGB1 release, other cytokines/cytotoxic proteins also contribute. Skin explant models represent a potential model of SJS/TEN that could be utilized for further mechanistic studies and targeted therapy screening.
- Open Access
- 26 December 2022
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 143 (6) , 1023-1030.e7
TNF-α‒Mediated Keratinocyte Expression and Release of Matrix Metalloproteinase 9: Putative Mechanism of Pathogenesis in Stevens‒Johnson Syndrome/Toxic Epidermal Necrolysis
- 26 December 2022
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 143 (6) , 1023-1030.e7
Open AccessTNF-α‒Mediated Keratinocyte Expression and Release of Matrix Metalloproteinase 9: Putative Mechanism of Pathogenesis in Stevens‒Johnson Syndrome/Toxic Epidermal Necrolysis
- Open Access
- 20 May 2021
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 39 (15_suppl) , 2643
Outcomes of immune checkpoint inhibitor-mediated colitis: Multicenter cohort study.
2643 Background: Immune checkpoint inhibitor (ICI)-mediated colitis (IMC) is a common and serious adverse event. Although small series have described the clinical presentation of IMC, large multicenter series that integrate clinical, endoscopic, and histologic findings are lacking. Methods: We retrospectively assessed patients who received ICI and had endoscopically confirmed IMC from 2010 to 2019. IMC was graded based on the CTCAE version 5.0 criteria. Multivariate logistic regression analyses were conducted to assess factors associated with recurrence of IMC symptoms and long duration of corticosteroids use (> 70 days). Results: 675 patients were included. 387 patients were males (57%). Median age was 63 years. Melanoma was the most common cancer type (327; 48%). Most (365; 54%) patients received CTLA-4 inhibitor ICI, as monotherapy or in combination with PD-(L)1. Median time from ICI therapy to IMC was 62 days. IMC was grade 2 in 335 (50%) patients, Grade 3 in 181 (27%), and grade 4 in 16 (3%). 155 (23%) patients had mucosal ulceration on endoscopy, 91 of them had severe features (deep, large, or multiple ulcers); 336 (50%) patients had non-ulcerative inflammation. The rest had normal endoscopic findings with histologic inflammation. Most patients were admitted to the hospital for management of IMC (405; 60%) and 16 (3%) needed ICU-level of care. Treatment included corticosteroids in 577 (85%) patients (median duration 52 days), TNF inhibitor in 245 (36%), and vedolizumab in 90 (13%). 202 (32%) patients had recurrent IMC after resolution of symptoms. On multivariate logistic regression, factors associated with IMC recurrence and long (> 70 days) duration of corticosteroid therapy were grade of IMC ( p = 0.049), treatment with infliximab or vedolizumab ( p = 0.044), presence of mucosal ulceration ( p = 0.034 ), or features of active histologic inflammation ( p = 0.076). Of note, patients with mucosal ulceration received infliximab or vedolizumab more frequently ( p < 0.001). For patients with grade 2 IMC, mucosal inflammation on endoscopy and delay in performing endoscopy with time from IMC onset to endoscopy more than a month were associated with IMC recurrence and longer duration of corticosteroid use ( p = 0.029 and p < 0.001, respectively). 16 (3%) patients had colonic perforation, 7 of them underwent surgical resection. No IMC-related death occurred. Conclusions: IMC is a clinically significant adverse event that can lead to premature termination of ICI therapy with high rates of hospital admission. Rarely, it results in colonic perforation requiring surgical intervention and ICU admission. Our data suggest that there is a utility of endoscopic and histologic evaluation in the prediction of worse outcomes from IMC. This finding is particularly important for grade 2 IMC as current guidelines do not recommend endoscopic evaluation for this group.
- 20 May 2021
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 39 (15_suppl) , 2643
Open AccessOutcomes of immune checkpoint inhibitor-mediated colitis: Multicenter cohort study.
2643 Background: Immune checkpoint inhibitor (ICI)-mediated colitis (IMC) is a common and serious adverse event. Although small series have described the clinical presentation of IMC, large multicenter series that integrate clinical, endoscopic, and histologic findings are lacking. Methods: We retrospectively assessed patients who received ICI and had endoscopically confirmed IMC from 2010 to 2019. IMC was graded based on the CTCAE version 5.0 criteria. Multivariate logistic regression analyses were conducted to assess factors associated with recurrence of IMC symptoms and long duration of corticosteroids use (> 70 days). Results: 675 patients were included. 387 patients were males (57%). Median age was 63 years. Melanoma was the most common cancer type (327; 48%). Most (365; 54%) patients received CTLA-4 inhibitor ICI, as monotherapy or in combination with PD-(L)1. Median time from ICI therapy to IMC was 62 days. IMC was grade 2 in 335 (50%) patients, Grade 3 in 181 (27%), and grade 4 in 16 (3%). 155 (23%) patients had mucosal ulceration on endoscopy, 91 of them had severe features (deep, large, or multiple ulcers); 336 (50%) patients had non-ulcerative inflammation. The rest had normal endoscopic findings with histologic inflammation. Most patients were admitted to the hospital for management of IMC (405; 60%) and 16 (3%) needed ICU-level of care. Treatment included corticosteroids in 577 (85%) patients (median duration 52 days), TNF inhibitor in 245 (36%), and vedolizumab in 90 (13%). 202 (32%) patients had recurrent IMC after resolution of symptoms. On multivariate logistic regression, factors associated with IMC recurrence and long (> 70 days) duration of corticosteroid therapy were grade of IMC ( p = 0.049), treatment with infliximab or vedolizumab ( p = 0.044), presence of mucosal ulceration ( p = 0.034 ), or features of active histologic inflammation ( p = 0.076). Of note, patients with mucosal ulceration received infliximab or vedolizumab more frequently ( p < 0.001). For patients with grade 2 IMC, mucosal inflammation on endoscopy and delay in performing endoscopy with time from IMC onset to endoscopy more than a month were associated with IMC recurrence and longer duration of corticosteroid use ( p = 0.029 and p < 0.001, respectively). 16 (3%) patients had colonic perforation, 7 of them underwent surgical resection. No IMC-related death occurred. Conclusions: IMC is a clinically significant adverse event that can lead to premature termination of ICI therapy with high rates of hospital admission. Rarely, it results in colonic perforation requiring surgical intervention and ICU admission. Our data suggest that there is a utility of endoscopic and histologic evaluation in the prediction of worse outcomes from IMC. This finding is particularly important for grade 2 IMC as current guidelines do not recommend endoscopic evaluation for this group.
- Open Access
- 15 March 2021
- Published by Springer Nature in British Journal of Cancer
- Vol. 124 (10) , 1661-1669
Checkpoint-blocker-induced autoimmunity is associated with favourable outcome in metastatic melanoma and distinct T-cell expression profiles
Background: Immune checkpoint blockers (ICBs) activate CD8+ T cells, eliciting both anti-cancer activity and immune-related adverse events (irAEs). The relationship of irAEs with baseline parameters and clinical outcome is unclear. Methods: Retrospective evaluation of irAEs on survival was performed across primary (N = 144) and secondary (N = 211) independent cohorts of patients with metastatic melanoma receiving single agent (pembrolizumab/nivolumab—sICB) or combination (nivolumab and ipilimumab—cICB) checkpoint blockade. RNA from pre-treatment and post-treatment CD8+ T cells was sequenced and differential gene expression according to irAE development assessed. Results: 58.3% of patients developed early irAEs and this was associated with longer progression-free (PFS) and overall survival (OS) across both cohorts (log-rank test, OS: P < 0.0001). Median survival for patients without irAEs was 16.6 months (95% CI: 10.9–33.4) versus not-reached (P = 2.8 × 10−6). Pre-treatment monocyte and neutrophil counts, but not BMI, were additional predictors of clinical outcome. Differential expression of numerous gene pathway members was observed in CD8+ T cells according to irAE development, and patients not developing irAEs demonstrating upregulated CXCR1 pre- and post-treatment. Conclusions: Early irAE development post-ICB is associated with favourable survival in MM. Development of irAEs is coupled to expression of numerous gene pathways, suggesting irAE development in-part reflects baseline immune activation.
- 15 March 2021
- Published by Springer Nature in British Journal of Cancer
- Vol. 124 (10) , 1661-1669
Open AccessCheckpoint-blocker-induced autoimmunity is associated with favourable outcome in metastatic melanoma and distinct T-cell expression profiles
Background: Immune checkpoint blockers (ICBs) activate CD8+ T cells, eliciting both anti-cancer activity and immune-related adverse events (irAEs). The relationship of irAEs with baseline parameters and clinical outcome is unclear. Methods: Retrospective evaluation of irAEs on survival was performed across primary (N = 144) and secondary (N = 211) independent cohorts of patients with metastatic melanoma receiving single agent (pembrolizumab/nivolumab—sICB) or combination (nivolumab and ipilimumab—cICB) checkpoint blockade. RNA from pre-treatment and post-treatment CD8+ T cells was sequenced and differential gene expression according to irAE development assessed. Results: 58.3% of patients developed early irAEs and this was associated with longer progression-free (PFS) and overall survival (OS) across both cohorts (log-rank test, OS: P < 0.0001). Median survival for patients without irAEs was 16.6 months (95% CI: 10.9–33.4) versus not-reached (P = 2.8 × 10−6). Pre-treatment monocyte and neutrophil counts, but not BMI, were additional predictors of clinical outcome. Differential expression of numerous gene pathway members was observed in CD8+ T cells according to irAE development, and patients not developing irAEs demonstrating upregulated CXCR1 pre- and post-treatment. Conclusions: Early irAE development post-ICB is associated with favourable survival in MM. Development of irAEs is coupled to expression of numerous gene pathways, suggesting irAE development in-part reflects baseline immune activation.
- Open Access
- 5 June 2020
- Published by Elsevier in Clinical Oncology
- Vol. 33 (1) , e50-e53
Coronavirus Disease 2019: the Pivotal Role of UK Clinical Oncology and the UK Coronavirus Cancer Monitoring Project
- 5 June 2020
- Published by Elsevier in Clinical Oncology
- Vol. 33 (1) , e50-e53
Open AccessCoronavirus Disease 2019: the Pivotal Role of UK Clinical Oncology and the UK Coronavirus Cancer Monitoring Project
- Open Access
- 1 May 2020
- Published by Elsevier in Gastroenterology
- Vol. 158 (6) , S-535-535
Su1185 IMMUNE CHECKPOINT INHIBITOR-RELATED COLITIS ASSESSMENT AND PROGNOSIS: CAN UCEIS, MAYO AND NANCY INDEX SCORING POINT THE WAY?
- 1 May 2020
- Published by Elsevier in Gastroenterology
- Vol. 158 (6) , S-535-535
Open AccessSu1185 IMMUNE CHECKPOINT INHIBITOR-RELATED COLITIS ASSESSMENT AND PROGNOSIS: CAN UCEIS, MAYO AND NANCY INDEX SCORING POINT THE WAY?
- Open Access
- 25 January 2019
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 13 (Supplement) , S137-S138
P100 Real-world data: the incidence, diagnosis, and management outcomes of patients with immunotherapy-related colitis in two tertiary centres
Checkpoint inhibitors are a novel anti-cancer therapy that are standard of care in metastatic melanoma, non-small cell lung and renal cancer. CTLA-4 inhibitors (eg, Ipilimumab) and PD-1 inhibitors (Nivolumab, Pembrolizumab) can be used separately or in combination for melanoma, whereas single PD-1 inhibitors are the norm for others. Their immune inhibition is non-specific, leading to a number of immune-related adverse events (irAEs), including colitis, hepatitis, and pancreatitis. Combination therapy is known to cause more irAEs than single-agent PD-1 inhibition. There are limited real-world clinical data describing the incidence and management of these GI irAEs. Retrospective two–centre (John Radcliffe Hospital in Oxford and Clatterbridge Cancer Centre in Liverpool) review. Melanoma, renal and lung cancer patients receiving Ipilimumab ± Nivolumab ± Pembrolizumab between December 2011 and June 2018 were identified from the oncology prescribing database. The electronic patient record (EPR) was used to determine the incidence of GI side effects. Investigations, treatment, and outcome data were collated. Of 1125 patients who had immunotherapy, 130 developed colitis (11.6%). In our cohort: (1) Median age was 66 (Males- Median 67, range 24–88; females: 64.5 range 27–86); (2) 60% were male; (3) 63.0% patients required admission (75% combination); (4) median length of admission is 4–7 days (6 combination); (5) presence of erosions or ulcers at endoscopy tended to predict a more severe outcome; (6) faecal calprotectin in steroid refractory cases was >300 in all patients where measured; (7) high proportion of patients receiving IV methylprednisolone 43.8% (66.7% combination); (8) significant proportion of patients requiring infliximab 21.5% (35% in combination therapy); (9) of those requiring infliximab, 64.3% (18/28) were male; (10) two patients with refractoriness to steroids and infliximab had vedolizumab; (11) colectomy rate 2.3% (3/130). Complete management and outcome data will be presented. Immunotherapy-related colitis is one of the more severe adverse events related to immunotherapy and a significant proportion of patients will require hospital admission. Steroid refractoriness is a significant problem and studies are required to elucidate optimum treatment regimens and escalation strategies. This has implications for standardisation of care and healthcare provision on already stretched budgets. Complete management and outcome data will be presented.
- 25 January 2019
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 13 (Supplement) , S137-S138
Open AccessP100 Real-world data: the incidence, diagnosis, and management outcomes of patients with immunotherapy-related colitis in two tertiary centres
Checkpoint inhibitors are a novel anti-cancer therapy that are standard of care in metastatic melanoma, non-small cell lung and renal cancer. CTLA-4 inhibitors (eg, Ipilimumab) and PD-1 inhibitors (Nivolumab, Pembrolizumab) can be used separately or in combination for melanoma, whereas single PD-1 inhibitors are the norm for others. Their immune inhibition is non-specific, leading to a number of immune-related adverse events (irAEs), including colitis, hepatitis, and pancreatitis. Combination therapy is known to cause more irAEs than single-agent PD-1 inhibition. There are limited real-world clinical data describing the incidence and management of these GI irAEs. Retrospective two–centre (John Radcliffe Hospital in Oxford and Clatterbridge Cancer Centre in Liverpool) review. Melanoma, renal and lung cancer patients receiving Ipilimumab ± Nivolumab ± Pembrolizumab between December 2011 and June 2018 were identified from the oncology prescribing database. The electronic patient record (EPR) was used to determine the incidence of GI side effects. Investigations, treatment, and outcome data were collated. Of 1125 patients who had immunotherapy, 130 developed colitis (11.6%). In our cohort: (1) Median age was 66 (Males- Median 67, range 24–88; females: 64.5 range 27–86); (2) 60% were male; (3) 63.0% patients required admission (75% combination); (4) median length of admission is 4–7 days (6 combination); (5) presence of erosions or ulcers at endoscopy tended to predict a more severe outcome; (6) faecal calprotectin in steroid refractory cases was >300 in all patients where measured; (7) high proportion of patients receiving IV methylprednisolone 43.8% (66.7% combination); (8) significant proportion of patients requiring infliximab 21.5% (35% in combination therapy); (9) of those requiring infliximab, 64.3% (18/28) were male; (10) two patients with refractoriness to steroids and infliximab had vedolizumab; (11) colectomy rate 2.3% (3/130). Complete management and outcome data will be presented. Immunotherapy-related colitis is one of the more severe adverse events related to immunotherapy and a significant proportion of patients will require hospital admission. Steroid refractoriness is a significant problem and studies are required to elucidate optimum treatment regimens and escalation strategies. This has implications for standardisation of care and healthcare provision on already stretched budgets. Complete management and outcome data will be presented.